Recruiting

Impact of Repeated Ischemic Preconditioning on Hemodynamic and Metabolic Parameters in Chronic Kidney Disease Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to investigate how repeated ischemic preconditioning affects various hemodynamic and metabolic parameters, such as SIRT-1 levels, blood saturation, IL-6 levels, blood pressure, and heart rate, in patients with chronic kidney disease, over a period of 7 days.

What is being tested

Preconditioning with Controlled Ischemia

+ Preconditioning with Controlled Ischemia

+ Preconditioning with Controlled Ischemia

Other
Who is being recruted

Urogenital Diseases+10

+ Chronic Disease

+ Female Urogenital Diseases and Pregnancy Complications

Over 18 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Interventional
Study Start: July 2026
See protocol details

Summary

Principal SponsorMedical University of Lodz
Study ContactMichał Nowicki, ProfessorMore contacts
Last updated: August 4, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 23, 2026

Actual date on which the first participant was enrolled.

This study focuses on understanding how repeated episodes of a process called 'ischemic preconditioning' affect blood pressure, heart rate, and inflammation markers in individuals with various stages of kidney disease. Ischemic preconditioning involves intentionally creating brief periods of reduced blood flow to potentially protect the heart and blood vessels from future damage. This research is important as it could help develop new strategies to prevent complications in people with kidney disease. The study takes place over four days during a hospital stay in the Department of Nephrology, Hypertension, Transplantology and Internal Diseases. During the study, participants will have their blood pressure and heart rate monitored, and a small amount of blood will be taken for laboratory tests. The ischemic preconditioning process involves applying pressure to the lower leg using a blood pressure cuff for four cycles of 5 minutes each. This procedure will be repeated over the next two days. On the final day, blood pressure, heart rate, and blood saturation will be measured again, and another blood sample will be taken for comparison. The study will assess changes in specific markers such as SIRT-1, IL-6, blood saturation, blood pressure, and heart rate, from the beginning to the end of the seven-day period.

Principal SponsorMedical University of Lodz
Study ContactMichał Nowicki, ProfessorMore contacts
Last updated: August 4, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

60 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesChronic DiseaseFemale Urogenital Diseases and Pregnancy ComplicationsKidney DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsUrologic DiseasesDisease AttributesRenal InsufficiencyFemale Urogenital DiseasesMale Urogenital DiseasesInflammationRenal Insufficiency, Chronic

Criteria

9 inclusion criteria required to participate
chronic kidney disease in stages G1-G5

consciousness disorders

failure to meet the qualification criteria for participation in the study

features of muscle cell damage (e.g. rhabdomyolysis)

Show More Criteria

1 exclusion criteria prevent from participating
-

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

This group includes patients with chronic kidney disease who are undergoing hemodialysis. They receive a special treatment called preconditioning with control ischemic episodes.

Group II

This group involves patients with Chronic Kidney Disease (CKD) stages G1-G5, excluding those on chronic hemodialysis. Participants undergo a preconditioning process with controlled ischemic episodes.

Group III

This group consists of patients without Chronic Kidney Disease (CKD).

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Recruiting

Medical University of Lodzi

Lodz, PolandOpen Medical University of Lodzi in Google Maps
Recruiting

Medical University of Lodzi

Lodz, Poland
Recruiting
2 Study Centers